Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.

@article{Schnichels2013ComparativeTA,
  title={Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.},
  author={Sven Schnichels and Ulrike Hagemann and Kai Januschowski and Johanna M. Hofmann and Karl-Ulrich Bartz-Schmidt and Peter Szurman and Martin S. Spitzer and Sabine Aisenbrey},
  journal={The British journal of ophthalmology},
  year={2013},
  volume={97 7},
  pages={
          917-23
        }
}
BACKGROUND/AIMS Vascular endothelial growth factor (VEGF) is a key factor in the pathogenesis of neovascular retinal diseases including age-related macular degeneration. VEGF inhibitors including ranibizumab, pegaptanib or bevacizumab improve retinal morphology and vision in many patients. The recently approved drug aflibercept (VEGF Trap-Eye/Eyelea, Regeneron, Tarrytown, New York, USA) offers a new therapy modality. We therefore tested for toxic and anti-proliferating effects of aflibercept… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells

Patrick R. Merz, Nina Röckel, Seda Ballikaya, Gerd U. Auffarth, Ingo Schmack
  • BMC Ophthalmology
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Intravitreal a fl ibercept ( VEGF TrapEye ) in wet age - related macular degeneration

JS Heier, DM Brown, V Chong
  • Ophthalmology
  • 2012